MapLight Therapeutics, Inc. (MPLT)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20260 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to MapLight Therapeutics, Inc.’s names, not what it holds today.
3 published
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Jan 30, 2025 | 2025/0032460 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Pharmaceuticals | MapLight Therapeutics, Inc. |
| Jun 13, 2024 | 2024/0189240 | PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLMITRIPTAN | Pharmaceuticals | MapLight Therapeutics, Inc. |
| Dec 8, 2022 | 2022/0387396 | METHODS OF TREATING THE SYMPTOMS OF AUTISM SPECTRUM DISORDER | Pharmaceuticals | MapLight Therapeutics, Inc. |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.